While cancer continues to claim 167,000 lives every year in the UK and ten million worldwide, research on a variety of treatment options is continually improving and expanding.
Only last week, we learnt of the results of a clinical trial which found that the drug Enhertu doubled average survival rates in women with breast cancer. Another revealed that after taking Dostarlimab, all patients in the drug trial seemed to be in remission. Then there were the results from the Phase I study involving a custom-made mRNA vaccine for pancreatic cancer, which produced promising results for the deadliest of cancers in a small initial trial.
